67 assets in Mixed Phenotype Acute Leukemia

Therapeutic assets addressing Mixed Phenotype Acute Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Midazolam Mixed Phenotype Acute Leukemia	Kura Oncology, Inc.	P1/2	CCC (48)
Orca-Q Mixed Phenotype Acute Leukemia	University of Florida	P1/2	CCC (48)
Ziftomenib Mixed Phenotype Acute Leukemia	Kura Oncology, Inc.	P1/2	CCC (48)
Apamistamab-B10-Astatine At-211 Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P1/2	CC (47)
Cpx-351 Mixed Phenotype Acute Leukemia	Children's Oncology Group	P1/2	CC (47)
Selinexor Mixed Phenotype Acute Leukemia	St. Jude Children's Research Hospital	P1	CC (47)
Icovamenib Mixed Phenotype Acute Leukemia	Biomea Fusion Inc.	P1	CC (43)
Ipilimumab Mixed Phenotype Acute Leukemia	National Cancer Institute (NCI)	P1	CC (43)
Mezigdomide Mixed Phenotype Acute Leukemia	Memorial Sloan Kettering Cancer Center	P1/2	CC (43)
Nivolumab Mixed Phenotype Acute Leukemia	National Cancer Institute (NCI)	P1	CC (43)
Recombinant Human Granulocyte Colony-Stimulating Factor Mixed Phenotype Acute Leukemia	University of Washington	P1/2	CC (43)
Uproleselan Mixed Phenotype Acute Leukemia	National Cancer Institute (NCI)	P1	CC (43)
Vnx-101 Mixed Phenotype Acute Leukemia	Vironexis Biotherapeutics Inc.	P1/2	CC (43)
cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr Mixed Phenotype Acute Leukemia	Fred Hutchinson Cancer Center	P1	C (39)
Mrx-2843 Mixed Phenotype Acute Leukemia	Meryx, Inc.	P1	C (39)
Orcagraft Mixed Phenotype Acute Leukemia	Orca Biosystems, Inc.	P1	C (39)
Tagraxofusp Mixed Phenotype Acute Leukemia	Therapeutic Advances in Childhood Leukemia Consortium	P1	C (39)

Showing 51 to 67 of 67 assets

PreviousPage 2 of 2Next